rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    SLS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Leukemia vaccine passes key trial, adding to breakthrough year for cancer drugs

      The vaccine reduced risk of death for certain acute myeloid leukemia patients, according to drugmaker

      22h agoThe Washington PostSLS
      Sellas Life Sciences stock falls on $150M stock offering
      Nov 17Investing.comSLS
      Sellas Life Sciences: REGAL Hits, But The Data Leaves Too Many Questions Unanswered

      Analyst rates Sellas Life Sciences a Sell: its roughly $4 billion valuation outstrips GPS's roughly $826 million risk-adjusted U.S.

      Nov 17Seeking AlphaSLS
      12 Health Care Stocks Moving In Tuesday's Intraday Session
      Nov 17BenzingaDARESLS
      Amer Sports, Sellas Life Sciences, Similarweb And Other Big Stocks Moving Higher On Tuesday
      Nov 17BenzingaSLSASSMWB
      SELLAS Stock Triples on Cancer Vaccine Cutting Death Risk by 41% in Pivotal Leukemia Trial,
      Nov 17BenzingaSLS
      Sellas Life Sciences stock hits 52-week high at 24.17 USD
      Nov 17Investing.comSLS
      Another Cancer Vaccine Just Scored. Shares Catapult 180%.

      It wasn't Merck and Moderna this time. A third player has entered the chat.

      Nov 17Investor's Business DailySLS
      Why is Sellas Life Sciences stock surging today?
      Nov 17Investing.comSLS
      SELLAS surges on late-stage trial win for cancer vaccine
      Nov 17Seeking AlphaSLS
      SELLAS Life Sciences stock soars 240% on positive cancer trial
      Nov 17Investing.comSLS
      Sellas’ GPS Cuts Death Risk By 41% In Pivotal AML Trial – Firm Eyes FDA Filing In First Half Of 2027
      Nov 17Yahoo FinanceSLS
      Sellas' cancer vaccine extends survival in blood cancer trial
      Nov 17ReutersSLS
      SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid Leukemia

      - REGAL trial met its primary endpoint with GPS demonstrating statistically significant and clinically meaningful reduction in risk of death by 41% with median overall survival of 24.0 months versus 14.7 months for best available treatment, and a hazard ratio of 0.59 (p=0.035) - - Company plans to meet with the U.S. Food and Drug Administration (FDA) while advancing preparations for a Biologics License Application (BLA) submission for GPS - - SELLAS to host webcast today, November 17, 2026, at 7

      Nov 17Yahoo FinanceSLS
      SLS Stock Jumps After-Hours: Retail Eyes Lilly’s Cancer Deal for Valuation Clues — 2 Big Investors Grab Shares
      Nov 17Yahoo FinanceSLSLLY
      12 Health Care Stocks Moving In Friday's Pre-Market Session
      Nov 13BenzingaSLS
      Sellas Life Sciences shares jump as key leukemia trial results near (SLS:NASDAQ)
      Nov 13Seeking AlphaSLS
      SELLAS Life Sciences Group (SLS) Stock Could Be Fully Priced On Phase 3 Analysis Trigger
      Nov 6Yahoo FinanceSLS
      SELLAS Life Sciences to Present Positive Phase 2 Data Demonstrating Encouraging Response and Survival Outcomes with SLS009 Combination in High-Risk AML at ASH 2026
      Nov 4Yahoo FinanceSLS
      SELLAS Life Sciences Group (SLS) Dropped, So What Is Behind The Latest Attention?
      Oct 29Yahoo FinanceSLS
      10 Health Care Stocks Whale Activity In Today’s Session
      Oct 28BenzingaSLS
      Sellas says REGAL trial nears final analysis (SLS:NASDAQ)

      SELLAS Life Sciences (SLS) stock fell as the company hits a final analysis milestone in its Phase 3 REGAL trial, setting up a topline data readout. Read more here.

      Oct 28Seeking AlphaSLS
      SELLAS Life Sciences Stock Stumbles: What's Going On?
      Oct 28BenzingaSLS
      Sellas Life Sciences phase 3 AML trial reaches key milestone
      Oct 28Investing.comSLS
      SELLAS Life Sciences Reaches 80th Event in Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia
      Oct 28Yahoo FinanceSLS
      Sellas Life Sciences: The Longer The Wait, The More Likely A REGAL Failure (NASDAQ:SLS)

      Sellas Life Sciences remains a 'Strong Sell,' as the REGAL trial delay signals increased risk of failure and diminished probability of success. Learn more about SLS stock here.

      Oct 28Seeking AlphaSLS
      SLS Stock Gets A BlackRock Spotlight Ahead Of Phase 3 AML Data — Bulls Spot 2027 European GPS Approval Forecast
      Oct 28Yahoo FinanceSLSBLK
      Sellas Life Sciences: Too Many Survivors For Its Own Trial Plan (NASDAQ:SLS)

      Sellas Life Sciences is a late-stage biotech with no product sales, hinging on its Phase 3 REGAL trial for GPS in AML. Click to know why I rate SLS stock a Hold.

      Oct 26Seeking AlphaSLS
      SLS Stock Jumps Overnight: Retail Eyes Huge Potential Buyout As CEO Marks 15 Years
      Oct 20Yahoo FinanceSLS
      SLS Stock Jumps Overnight: Retail Sees Big Pharma Buyout Clues In 'M&A Negotiation Lounge' Booth At ASH
      Oct 12Yahoo FinanceSLS
      Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3

      Shares of Sellas Life Sciences Group Inc. (NASDAQ:SLS) nosedived by 16.6 percent in the third quarter of the year—from $14.76 on June 30 to $12.31 on Wednesday—as sentiment was dragged down by the delays and uncertainties surrounding the clinical results of its treatment candidate for acute myeloid leukemia (AML). In Wednesday’s trading alone, the stock […]

      Oct 1Yahoo FinanceSLS
      Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge?
      Oct 1Yahoo FinanceSLS
      SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer Data

      SELLAS Life Sciences Group has delivered a very large 3 year return, which puts a spotlight on whether the current share price around US$11.51 still lines up with what its balance sheet is worth on paper. With that kind of move behind it and new cancer therapy data in play, the question now is how much value investors are effectively placing on SELLAS' book value. Over the past 3 years, the stock has gained roughly 7x. This makes the relationship between its recent share price performance...

      Sep 30Yahoo FinanceSLS
      SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data
      Sep 30Yahoo FinanceSLS
      SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer

      SLS009 increased apoptosis more than six-fold versus daraxonrasib in a MYC-amplified, daraxonrasib-resistant patient-derived pancreatic cancer organoid model - Combination of SLS009 and daraxonrasib further increased apoptosis to 36.5% and necrosis to 30.6%, supporting evaluation of CDK9 inhibition as a potential strategy to enhance RAS-directed therapy -SLS009 combined with BET inhibition demonstrated synergistic activity and sustained suppression of MYC, providing additional evidence of SLS009

      Sep 25Yahoo FinanceSLS
      SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered
      Sep 25Yahoo FinanceSLS
      SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial

      Sellas said earlier laboratory work showed activity against pancreatic cancer cells resistant to RAS-targeting drugs.

      Sep 24Yahoo FinanceSLS
      Sellas Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced In

      SELLAS Life Sciences is rated Hold, with a $9.25 price target, as the current valuation reflects REGAL trial success probability. Read more on SLS stock here.

      Sep 21Seeking AlphaSLS
      SELLAS Life Sciences Group (SLS) Lands 3 AACR Abstracts For SLS009 Pancreatic Cancer Data

      SELLAS Life Sciences Group (NasdaqCM:SLS) will present new preclinical data on SLS009 in pancreatic ductal adenocarcinoma at the 2026 AACR Conference. Three abstracts on SLS009 have been accepted, focusing on its mechanism of action and activity in KRAS mutant pancreatic cancer models. The research is being carried out with a respected academic institution and adds detail on SLS009 within SELLAS Life Sciences Group's preclinical pipeline. Interest in SELLAS Life Sciences Group reflects a...

      Sep 3Yahoo FinanceSLS
      SELLAS Life Sciences to Present Preclinical Data on SLS009 in Pancreatic Ductal Adenocarcinoma at the 2026 AACR Conference on Pancreatic Cancer

      - Three posters to highlight preclinical activity of SLS009 (tambiciclib) across patient-derived KRAS mutant organoid models of pancreatic cancer – - Studies conducted in collaboration with the University of Wisconsin School of Medicine and Public Health - NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer

      Sep 2Yahoo FinanceSLS
      Why Analysts Think Sellas Life Sciences Stock Can Gain 150% From Here
      Sep 1BarchartSLS
      Sellas CEO Stergiou Says ‘Rigorous, Unblinded’ Data From Pivotal AML Trial Will 'Speak For Itself' As REGAL Catalyst Nears
      Aug 31Yahoo FinanceSLS
      Social Buzz: Wallstreetbets Stocks Mixed Premarket Monday; SELLAS Life Sciences to Advance, Tesla to Decline

      The most-talked-about stocks in the Reddit subforum Wallstreetbets were mixed hours before Monday's

      Aug 31Yahoo FinanceSLS
      SLS Stock Looks Like a $3 Billion Biotech Winner—This Short Seller Says the Market Has It Dangerously Wrong: 'Most Expensive Coin Flip' (UPDATED)

      Editor’s Note: The story has been refreshed with the latest market price action and a revised headline. Short seller BMF Capital disclosed a short position in SELLAS Life Sciences Group Inc., arguing the market has “dangerously overvalued” the biotech company...

      Aug 31Yahoo FinanceSLS
      BMF Capital Shorts SELLAS Life Sciences, Sees 76% Downside - SELLAS Life Sciences Gr (NASDAQ:SLS)
      Aug 31BenzingaSLS
      Sellas Life (SLS) Falls 13% as Firm Still Mum on ALM Drug Candidate

      Sellas Life Sciences (NASDAQ:SLS) saw its share price decline by 13.15 percent on Friday to close at $13.21 apiece, as investors turned increasingly concerned about the company’s silence about its treatment candidate for acute myeloid leukemia (AML). The drop was triggered by a report from a Germany-based news site that the company has already hit […]

      Aug 29Yahoo FinanceSLS
      When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
      Aug 27BenzingaRVMDSLS
      Sellas Traders See Pancreatic Cancer Race After RVMD’s Drug Approval — But Near-Term Focus Remains On SLS’s Leukemia Pipeline
      Aug 26Yahoo FinanceSLS
      SLS, IBRX Catch The Eye Of A Major US Pension Fund — And Big Clinical Catalysts Are On The Horizon

      Virginia Retirement System disclosed SLS and IBRX stakes worth nearly $909,000 combined.

      Aug 26Yahoo FinanceSLS
      SLS Traders Eye This Important Resistance Zone Ahead Of Key AML Data Readout

      Sellas shares reached a swing high of $15.88 in late June before tumbling 42% to a July low of $9.19.

      Aug 24Yahoo FinanceSLS

      This is the newest page. Registered accounts read further back.